Rui M. Tostões, Sofia B. Leite, Margarida Serra, Janne Jensen, Petter Björquist, Manuel J. T. Carrondo, Catarina Brito, Paula M. Alves – 26 October 2011 – Primary cultures of human hepatocyte spheroids are a promising in vitro model for long‐term studies of hepatic metabolism and cytotoxicity. The lack of robust methodologies to culture cell spheroids, as well as a poor characterization of human hepatocyte spheroid architecture and liver‐specific functionality, have hampered a widespread adoption of this three‐dimensional culture format.

Katrin Friedbichler, Madeleine Themanns, Kristina M. Mueller, Michaela Schlederer, Jan‐Wilhelm Kornfeld, Luigi M. Terracciano, Andrey V. Kozlov, Susanne Haindl, Lukas Kenner, Thomas Kolbe, Mathias Mueller, Kenneth J. Snibson, Markus H. Heim, Richard Moriggl – 26 October 2011 – Persistently high levels of growth hormone (GH) can cause liver cancer. GH activates multiple signal‐transduction pathways, among them janus kinase (JAK) 2‐signal transducer and activator of transcription (STAT) 5 (signal transducer and activator of transcription 5).

Stefan G. Hübscher – 17 October 2011

Benjamin H. Friedman, Joshua H. Wolf, Liqing Wang, Mary E. Putt, Abraham Shaked, Jason D. Christie, Wayne W. Hancock, Kim M. Olthoff – 17 October 2011 – Early allograft dysfunction (EAD) occurring in the first week post‐liver transplantation is associated with increased graft failure and mortality and is believed to be largely due to ischemia/reperfusion injury.

Vinay Sundaram, Jawad Ahmad – 17 October 2011

Parsia A. Vagefi, Nancy L. Ascher, Chris E. Freise, Jennifer L. Dodge, John P. Roberts – 17 October 2011 – The demographics of patients in the United States who undergo living donor liver transplantation (LDLT) versus patients who undergo deceased donor liver transplantation (DDLT) are interesting with respect to the demographics of the donor service areas (DSAs). We examined adult recipients of primary, non–status 1 liver‐only transplants from 2003 to 2009. The likelihood of undergoing LDLT was compared to the likelihood of undergoing DDLT by multivariate logistic regression.

P. Thomas Cherian, Wesal Alrabih, Abdel Douiri, Alberto Quaglia, Michael A. Heneghan, John O'Grady, Mohamed Rela, Nigel D. Heaton – 17 October 2011 – Liver transplantation (LT) for human immunodeficiency virus (HIV)–positive recipients with end‐stage liver disease has become an accepted practice. However, because these patients are increasingly being recognized as prothrombotic, we reviewed their posttransplant thrombotic complications.

Emanuela Giampalma, Matteo Renzulli, Cristina Mosconi, Giorgio Ercolani, Antonio Daniele Pinna, Rita Golfieri – 17 October 2011 – In liver transplantation (LT), biliary strictures (BSs) are among the most common complications. The aim of this study was to evaluate the efficacy of percutaneous treatments in the management of post‐LT BSs. Between 1999 and 2007, 48 patients underwent percutaneous treatments for posttransplant BSs.

Mamatha Bhat, Peter Ghali, Philip Wong, Victoria Marcus, René Michel, Marcelo Cantarovich, Peter Metrakos, Marc Deschenes – 17 October 2011

Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, Patrick Marcellin, Daniel Sereni, Hartwig Klinker, Christophe Moreno, Jean‐Pierre Zarski, Yves Horsmans, Hongmei Mo, Sarah Arterburn, Steven Knox, David Oldach, John G. McHutchison, Michael P. Manns, Graham R. Foster – 17 October 2011 – Tegobuvir (GS‐9190), a non‐nucleoside nonstructural protein (NS)5B polymerase inhibitor, and GS‐9256, an NS3 serine protease inhibitor, individually have activity against hepatitis C virus (HCV) genotype 1.